The Role of Proopiomelanocortin and α-Melanocyte-Stimulating Hormone in the Metabolic Syndrome in Psychiatric Disorders: A Narrative Mini-Review.
HPA axis
PTSD
melanocyte stimulating hormone (MSH)
metabolic syndrome
posttraumatic stress disorder
proopiomelanocortin (POMC)
schizophrenia
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
08
2019
accepted:
21
10
2019
entrez:
5
12
2019
pubmed:
5
12
2019
medline:
5
12
2019
Statut:
epublish
Résumé
The metabolic syndrome (MetS) comprises abdominal obesity, preclinical or full diabetes type 2, arterial hypertension, and dyslipidemia and affects a significant proportion of the general population with a remarkably higher prevalence in patients suffering from psychiatric disorders. However, studies exploring the pathogenetic link between MetS and psychiatric diseases are rare. Here, we aim to narrow this gap in knowledge by providing a narrative review on this topic that focuses on two psychiatric diseases, namely on schizophrenia and posttraumatic stress disorder (PTSD) since we assume them to be associated with two different main causalities of MetS: in schizophrenia, MetS evidently develops or aggravates in response to antipsychotic drug treatment while it assumingly develops in response to stress-induced endocrine and/or epigenetic alterations in PTSD. First, we compared the prevalences of MetS and associated pathologies (which we took from the latest meta-analyses) among different psychiatric disorders and were surprised that the prevalences of arterial hypertension and hyperglycemia in PTSD almost doubles those of the other psychiatric disorders. Next, we performed a literature search on the neurobiology of MetS and found numerous articles describing a role for proopiomelanocortin (POMC) in MetS. Thus, we concentrated further analysis on POMC and one of its downstream effector hormones, α-melanocyte-stimulating hormone (α-MSH). We found some evidence for a role of POMC in both PTSD and schizophrenia, in particular in antipsychotic-induced MetS, as well as for α-MSH in schizophrenia, but, surprisingly, no study on α-MSH in PTSD. Taken together, our synopsis reveals, first, a potential interaction between the POMC system and stress in the assumingly at least partially shared pathogenesis of psychiatric disorders and MetS, second, that modulation of the POMC system, in particular of the melanocortin 3 and 4 receptors, might be a promising target for the treatment of MetS and, third, that the DNA methylation status of
Identifiants
pubmed: 31798479
doi: 10.3389/fpsyt.2019.00834
pmc: PMC6867997
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
834Informations de copyright
Copyright © 2019 Raue, Wedekind, Wiltfang and Schmidt.
Références
FASEB J. 2013 Jun;27(6):2504-12
pubmed: 23475851
J Mol Endocrinol. 2017 Jul;59(1):81-92
pubmed: 28500249
Am J Psychiatry. 2013 Mar;170(3):265-74
pubmed: 23361837
Behav Brain Res. 2017 Jul 28;331:30-37
pubmed: 28527693
Alcohol Alcohol. 2016 Sep;51(5):515-21
pubmed: 27337988
J Neuroendocrinol. 2003 Aug;15(8):811-2
pubmed: 12834443
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
Dialogues Clin Neurosci. 2018 Mar;20(1):63-73
pubmed: 29946213
Biol Psychiatry. 2009 Jul 1;66(1):91-3
pubmed: 19344891
Psychoneuroendocrinology. 2013 Mar;38(3):341-7
pubmed: 22840286
Curr Psychiatry Rep. 2014 Oct;16(10):473
pubmed: 25138234
Front Neurosci. 2017 Jul 28;11:432
pubmed: 28804444
Neurobiol Dis. 2013 Apr;52:24-37
pubmed: 22426398
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
Neuropeptides. 2016 Aug;58:93-101
pubmed: 26775231
Behav Brain Res. 2013 Aug 1;250:139-47
pubmed: 23680165
Metabolism. 2015 Aug;64(8):926-33
pubmed: 25982700
Psychoneuroendocrinology. 2019 Apr;102:24-36
pubmed: 30503781
Asia Pac Psychiatry. 2017 Mar;9(1):
pubmed: 27804260
Curr Mol Pharmacol. 2015;9(2):126-40
pubmed: 25986564
Int J Neuropsychopharmacol. 2013 Feb;16(1):105-20
pubmed: 22176700
PLoS One. 2009 Aug 19;4(8):e6696
pubmed: 19690620
Am J Psychiatry. 2006 Jul;163(7):1273-6
pubmed: 16816234
Psychoneuroendocrinology. 2017 Sep;83:135-141
pubmed: 28623762
Dev Psychopathol. 2016 Nov;28(4pt2):1401-1412
pubmed: 26753719
Annu Rev Physiol. 2017 Feb 10;79:209-236
pubmed: 28192062
Int J Obes (Lond). 2014 Feb;38(2):163-9
pubmed: 23774329
Arch Neurol. 2009 Mar;66(3):300-5
pubmed: 19273747
Am J Psychiatry. 2003 Feb;160(2):290-6
pubmed: 12562575
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Jun;159(2):208-14
pubmed: 25485531
P T. 2014 Sep;39(9):638-45
pubmed: 25210417
Schizophr Bull. 2013 Mar;39(2):295-305
pubmed: 22927670
Alzheimers Dement. 2014 Jun;10(3 Suppl):S155-65
pubmed: 24924667
Schizophr Bull. 2016 Nov;42(6):1418-1437
pubmed: 27217270
Mol Psychiatry. 2012 Mar;17(3):242-66
pubmed: 21894153
Neuroscience. 2013 Sep 26;249:172-91
pubmed: 23298853
Psychiatry Res. 2018 Jul;265:284-291
pubmed: 29775885
Neurosci Biobehav Rev. 2018 Nov;94:49-58
pubmed: 30125600
Psychoneuroendocrinology. 2015 May;55:102-15
pubmed: 25745955
Diabetes Care. 2005 Feb;28(2):391-7
pubmed: 15677798
Am J Psychiatry. 1999 Nov;156(11):1686-96
pubmed: 10553730
J Steroid Biochem Mol Biol. 2017 Jan;165(Pt A):114-120
pubmed: 27002803
Psychiatry Clin Neurosci. 2015 May;69(5):243-58
pubmed: 25296946
Psychol Med. 2014 Jul;44(10):2017-28
pubmed: 24262678
PLoS One. 2014 Aug 01;9(8):e104160
pubmed: 25084453
Pharmacol Rep. 2016 Apr;68(2):292-6
pubmed: 26922530
Chronic Stress (Thousand Oaks). 2017 Jan-Dec;1:null
pubmed: 29862379
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2985-3023
pubmed: 24239920
J Physiol. 2009 Oct 15;587(Pt 20):4963-76
pubmed: 19723777
Psychopharmacology (Berl). 2006 Mar;185(1):11-8
pubmed: 16432682
Child Abuse Negl. 2015 Jul;45:154-62
pubmed: 25770346
Adv Exp Med Biol. 2017;960:1-17
pubmed: 28585193
Prev Chronic Dis. 2017 Mar 16;14:E24
pubmed: 28301314
Nutrition. 2000 Oct;16(10):924-36
pubmed: 11054598
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Aug 1;78:34-50
pubmed: 28438472
Endocr Rev. 2006 Dec;27(7):779-93
pubmed: 17122357
World Psychiatry. 2011 Jun;10(2):138-51
pubmed: 21633691
Curr Pharm Des. 2015;21(23):3352-8
pubmed: 26088111
Addict Biol. 2015 Mar;20(2):324-35
pubmed: 24612112
Addict Behav. 1998 Nov-Dec;23(6):827-40
pubmed: 9801719
Eur Neuropsychopharmacol. 1995 Dec;5(4):437-40
pubmed: 8998394
Schizophr Bull. 2013 Mar;39(2):306-18
pubmed: 22207632
Front Endocrinol (Lausanne). 2018 Apr 23;9:144
pubmed: 29740394
Curr Obes Rep. 2012 Mar;1(1):16-25
pubmed: 22943039
Endocr Metab Immune Disord Drug Targets. 2015;15(4):252-60
pubmed: 26100432
Schizophr Res. 2016 Jan;170(1):1-17
pubmed: 26621002
J Obes. 2012;2012:572848
pubmed: 22523667
Neurosci Biobehav Rev. 2015 Sep;56:15-25
pubmed: 26116876
Patient Relat Outcome Meas. 2014 Jun 23;5:43-62
pubmed: 25061342
J Psychiatr Res. 2010 Oct;44(13):827-33
pubmed: 20176366
J Clin Med Res. 2018 Jun;10(6):453-460
pubmed: 29707086
Transl Psychiatry. 2017 Jan 24;7(1):e1007
pubmed: 28117839
PLoS One. 2014 Apr 24;9(4):e94112
pubmed: 24763306
Harv Rev Psychiatry. 2016 Jul-Aug;24(4):271-93
pubmed: 27384397
Alcohol Clin Exp Res. 2014 Jun;38(6):1689-96
pubmed: 24818654
World Psychiatry. 2015 Oct;14(3):339-47
pubmed: 26407790
Front Neurosci. 2013 Feb 22;7:19
pubmed: 23440036
Annu Rev Psychol. 2008;59:55-92
pubmed: 18154499
J Clin Invest. 2013 Dec;123(12):5061-70
pubmed: 24177424
Pharmacol Res. 2015 May-Jun;95-96:20-6
pubmed: 25782398